BridgeBio Pharma. has been granted a patent for high-load tablet formulations of AG10, comprising 40-85% AG10 by weight, along with specific proportions of fillers, disintegrants, and lubricants. The formulations utilize high-grade microcrystalline cellulose with distinct morphological characteristics. GlobalData’s report on BridgeBio Pharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on BridgeBio Pharma, was a key innovation area identified from patents. BridgeBio Pharma's grant share as of June 2024 was 16%. Grant share is based on the ratio of number of grants to total number of patents.
High-load tablet formulations of ag10
The granted patent US12005043B2 outlines a novel tablet formulation that includes AG10 or its pharmaceutically acceptable salt, combined with various excipients such as fillers, disintegrants, and lubricants. The formulation specifies that AG10 should constitute 40 to 85% by weight, with fillers making up 5 to 55%, disintegrants 3 to 8%, and lubricants 0.5 to 3%. Notably, the fillers must include high-grade microcrystalline cellulose characterized by either spherical morphology and porous structure or needle-like particle shape. The patent further details specific weight percentages for AG10 and fillers, as well as preferred disintegrants like croscarmellose sodium and lubricants such as magnesium stearate.
Additionally, the patent claims methods for treating transthyretin amyloid (ATTR) cardiomyopathy and polyneuropathy through the administration of the described tablet formulation. The dissolution characteristics of the tablet are also emphasized, with requirements for at least 75% dissolution in a specific acidic solution within a defined timeframe. The formulation may also include a coating agent, enhancing its stability and efficacy. Overall, the patent presents a comprehensive approach to formulating AG10 tablets aimed at addressing specific amyloid-related conditions, highlighting both the composition and therapeutic applications of the formulation.
To know more about GlobalData’s detailed insights on BridgeBio Pharma, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
